phenazine hydrochloride | 14031-04-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: phenazine hydrochloride
• 英文别名: Phenazin; Hydrochlorid；2-Phenylpropylhydrazine hydrochloride；phenazine;hydrochloride
• CAS: 14031-04-0
• 化学式: C₁₂H₈N₂*ClH
• 分子量: 216.67
• InChiKey: GRJKNFXGXZQVBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.79
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  27
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  phenazine hydrochloride 、 hemicucurbit[6]uril 以 氯仿 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Host–guest interaction of hemicucurbiturils with phenazine hydrochloride salt

  摘要：

  The host-guest interactions between phenazine hydrochloride salt (PheH(+)) and hemicucurbit[n]uril (n=6 or 12) (HemiQ[6 or 12]) have been studied by H-1 NMR, UV-vis, IR, mass spectrometry (MS) and quantum chemistry. In H-1 NMR spectra, the broadening of proton resonances of the hosts suggests the interactions of PheH(+) with HemiQs. The quantitative stabilities of the host-guest systems have been obtained by UV-vis titration experiments, that is, the stoichiometric interactions of PheH(+) with HemiQ[6] have been observed with an association constant of K-a=(2.5 +/- 1.2)x10(6)Lmol(-1), while the 2:1 ratio complexes of PheH(+) with HemiQ[12] are formed with stepwise association constants of K-1=(9.2 +/- 2.8)x10(4)Lmol(-1) and K-2=(6.4 +/- 0.9)x10(5)Lmol(-1), respectively, which induce a total association constant of K-a=5.9x10(10)L(2)mol(-2). Both the 1:1 and 2:1 complexes have been detected by MS. Quantum chemistry calculations have been used to understand the static structures and thermodynamic stabilities of the supramolecular assemblies.

  DOI：

  10.1080/10610278.2014.904866
• 作为产物：
  描述：

  酚嗪 在 盐酸 作用下， 以 甲醇 、 氯仿 、 水 为溶剂， 以74.8%的产率得到phenazine hydrochloride
  参考文献：
  名称：

  Host–guest interaction of hemicucurbiturils with phenazine hydrochloride salt

  摘要：

  The host-guest interactions between phenazine hydrochloride salt (PheH(+)) and hemicucurbit[n]uril (n=6 or 12) (HemiQ[6 or 12]) have been studied by H-1 NMR, UV-vis, IR, mass spectrometry (MS) and quantum chemistry. In H-1 NMR spectra, the broadening of proton resonances of the hosts suggests the interactions of PheH(+) with HemiQs. The quantitative stabilities of the host-guest systems have been obtained by UV-vis titration experiments, that is, the stoichiometric interactions of PheH(+) with HemiQ[6] have been observed with an association constant of K-a=(2.5 +/- 1.2)x10(6)Lmol(-1), while the 2:1 ratio complexes of PheH(+) with HemiQ[12] are formed with stepwise association constants of K-1=(9.2 +/- 2.8)x10(4)Lmol(-1) and K-2=(6.4 +/- 0.9)x10(5)Lmol(-1), respectively, which induce a total association constant of K-a=5.9x10(10)L(2)mol(-2). Both the 1:1 and 2:1 complexes have been detected by MS. Quantum chemistry calculations have been used to understand the static structures and thermodynamic stabilities of the supramolecular assemblies.

  DOI：

  10.1080/10610278.2014.904866

文献信息

• [EN] INHIBITING CONNEXIN 46 TO TREAT GLIOBLASTOMA AND OTHER CONDITIONS<br/>[FR] INHIBITION DE LA CONNEXINE 46 POUR TRAITER UN GLIOBLASTOME ET D'AUTRES ÉTATS
  申请人：CLEVELAND CLINIC FOUND

  公开号：WO2019060409A1

  公开（公告）日：2019-03-28

  Provided herein are compositions, systems, kits, and methods for treating a disease or condition by administering to a subject an agent that inhibits connexin 46 (Cx46) (e.g., ondancetron, an ondancetron analog or derivative, testosterone, a testosterone analog or derivative, clozapine or a clozapine analog or derivative, or clofazimine or a clofazimine analog or derivative). In certain embodiments, the agent inhibits connexin 46-mediated gap junction intercellular connections (GJICs), and/or inhibits connexin 46, but does not inhibit connexin 43, connexin 45, and connexin 37 (e.g., in a human subject). In certain embodiments, the disease or condition is selected from brain cancer (e.g., glioblastoma), deafness, cataracts, or a skin disease.

  本文提供了一种通过向受体施用抑制连接蛋白46（Cx46）的药物（例如ondancetron、ondancetron类似物或衍生物、睾酮、睾酮类似物或衍生物、氯氮平或氯氮平类似物或衍生物、或氯硝唑或氯硝唑类似物或衍生物）来治疗疾病或症状的组合物、系统、套件和方法。在某些实施例中，该药物抑制Cx46介导的间隙连接细胞间联系（GJICs），并/或抑制Cx46，但不抑制Cx43、Cx45和Cx37（例如在人体受体中）。在某些实施例中，所述疾病或症状为脑癌（例如胶质母细胞瘤）、聋、白内障或皮肤病。
• Agent for simultaneously dying and bringhtening keratin fibers
  申请人：Sallwey Anette

  公开号：US20050257328A1

  公开（公告）日：2005-11-24

  The present patent application concerns an agent for the simultaneous brightening and coloring of keratin fibers, said agent being characterized in that it contains at least one peroxy salt and at least one dye resistant to peroxy salts which is taken from the group consisting of azo dyes, quinone dyes, triphenylmethane dyes, nitro dyes, acid dyes and basic dyes.

  本专利申请涉及一种用于同时对角蛋白纤维进行增亮和着色的制剂，其特征在于该制剂含有至少一种过氧盐和至少一种耐过氧盐的染料，这些染料来自偶氮染料、醌染料、三苯基甲烷染料、硝基染料、酸性染料和碱性染料组成的组。
• Claus, Chemische Berichte, 1875, vol. 8, p. 602
  作者：Claus

  DOI：——

  日期：——
• COSMETIC COMPOSITION COMPRISING A HYDROCALCHONE AND OPTIONALLY RETINOL OR A DERIVATIVE THEREOF
  申请人：UNILEVER PLC

  公开号：EP0725623A1

  公开（公告）日：1996-08-14
• SOLUBLE SOLID HAIR COLORING ARTICLE
  申请人：FELTS Timothy James

  公开号：US20120297556A1

  公开（公告）日：2012-11-29

  A soluble solid hair coloring article having cationic direct dye and one or more soluble porous solids containing nonionic surfactant, cationic surfactant, or a mixture thereof, such that the one or more soluble porous solids have a density of from about 0.03 g/cm3 to about 0.15 g/cm3; and methods of applying the soluble solid hair coloring article to hair.